NuCana plc presented promising data from its Phase 2 NuTide:701 study, showcasing the potential of NUC-7738 in combination with Merck’s Keytruda for treating metastatic melanoma. The combination showed encouraging efficacy signals and a favorable safety profile in patients who had previously failed PD-1 inhibitor therapies.